NASDAQ:FUSN - Nasdaq - CA36118A1003 - Common Stock - Currency: USD
Overall FUSN gets a fundamental rating of 3 out of 10. We evaluated FUSN against 556 industry peers in the Biotechnology industry. While FUSN seems to be doing ok healthwise, there are quite some concerns on its profitability. FUSN is quite expensive at the moment. It does show a decent growth rate.
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.2% | ||
ROE | -43.12% | ||
ROIC | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Altman-Z | 11.27 |
Industry Rank | Sector Rank | ||
---|---|---|---|
Current Ratio | 10.64 | ||
Quick Ratio | 10.64 |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
P/FCF | N/A | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
21.55
+0.03 (+0.14%)
Industry Rank | Sector Rank | ||
---|---|---|---|
Dividend Yield | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
PE | N/A | ||
Fwd PE | N/A | ||
P/S | 898.55 | ||
P/FCF | N/A | ||
P/OCF | N/A | ||
P/B | 7.58 | ||
P/tB | 7.58 | ||
EV/EBITDA | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
ROA | -32.2% | ||
ROE | -43.12% | ||
ROCE | N/A | ||
ROIC | N/A | ||
ROICexc | N/A | ||
ROICexgc | N/A | ||
OM | N/A | ||
PM (TTM) | N/A | ||
GM | N/A | ||
FCFM | N/A |
Industry Rank | Sector Rank | ||
---|---|---|---|
Debt/Equity | 0.21 | ||
Debt/FCF | N/A | ||
Debt/EBITDA | N/A | ||
Cap/Depr | 278.83% | ||
Cap/Sales | 196.28% | ||
Interest Coverage | N/A | ||
Cash Conversion | N/A | ||
Profit Quality | N/A | ||
Current Ratio | 10.64 | ||
Quick Ratio | 10.64 | ||
Altman-Z | 11.27 |